Literature DB >> 20661146

Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects.

Marissa DaSilva1, Monica O'Brien Deming, Suzanne E G Fligiel, Michael K Dame, Kent J Johnson, Richard D Swartz, James Varani.   

Abstract

OBJECTIVE: Nephrogenic systemic fibrosis is a clinical syndrome occurring in a small subset of patients with end-stage renal disease (ESRD). Exposure to certain of the gadolinium-based contrast agents during magnetic resonance imaging appears to be a trigger. The pathogenesis of the disease is largely unknown. The present study addresses potential pathophysiologic mechanisms.
MATERIALS AND METHODS: We have compared responses in organ-cultured skin and skin fibroblasts from individuals with ESRD to responses of healthy control subjects to Omniscan treatment.
RESULTS: Treatment of skin from ESRD patients with Omniscan stimulated production of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1, but not type I procollagen. The same treatment also stimulated an increase in hyaluronan production. Similar results were seen with skin from normal controls but basal levels were higher in ESRD patients. Fibroblasts in monolayer culture gave the same responses, but there were no differences based on whether the cells were isolated from the skin of healthy subjects or those with ESRD.
CONCLUSION: These data indicate that Omniscan exposure alters an enzyme/inhibitor system responsible for regulating collagen turnover in the skin and directly stimulates hyaluronan production. The higher basal levels of type I procollagen, matrix metalloproteinase-1, tissue inhibitor of metalloproteinases-1, and hyaluronan in the skin from ESRD patients could contribute to the sensitivity of this patient population to fibrotic changes, which might be induced by exposure to some of the gadolinium-based contrast agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20661146      PMCID: PMC3164303          DOI: 10.1097/RLI.0b013e3181e9436b

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  61 in total

Review 1.  Gadolinium and lanthanum: a iatrogenic transmetallation?

Authors:  Simona Brambilla; Serenella Valaperta; Giorgio Graziani; Alessandro Montanelli
Journal:  Clin Biochem       Date:  2008-06-03       Impact factor: 3.281

Review 2.  Extracellular gadolinium contrast agents: differences in stability.

Authors:  S K Morcos
Journal:  Eur J Radiol       Date:  2008-03-14       Impact factor: 3.528

3.  Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand.

Authors:  Martin A Sieber; Philipp Lengsfeld; Jakob Walter; Heiko Schirmer; Thomas Frenzel; Fred Siegmund; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  J Magn Reson Imaging       Date:  2008-05       Impact factor: 4.813

Review 4.  Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.

Authors:  Jean-Marc Idée; Marc Port; Christelle Medina; Eric Lancelot; Emmanuelle Fayoux; Sébastien Ballet; Claire Corot
Journal:  Toxicology       Date:  2008-03-22       Impact factor: 4.221

5.  Depressive symptoms and proinflammatory cytokine levels in chronic renal failure patients.

Authors:  Erkan Dervisoglu; Hale Maral Kir; Betul Kalender; Ceyla Eraldemir; Cigdem Caglayan
Journal:  Nephron Clin Pract       Date:  2008-04-17

6.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors:  Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

Review 7.  Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.

Authors:  Dale R Broome
Journal:  Eur J Radiol       Date:  2008-03-26       Impact factor: 3.528

8.  Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.

Authors:  M Edward; J A Quinn; S Mukherjee; M-B V Jensen; A G Jardine; P B Mark; A D Burden
Journal:  J Pathol       Date:  2008-04       Impact factor: 7.996

Review 9.  Tissue deposition of gadolinium and development of NSF: a convergence of factors.

Authors:  Mark A Perazella
Journal:  Semin Dial       Date:  2008-01-23       Impact factor: 3.455

10.  Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation.

Authors:  Guangyan Cai; Xueguang Zhang; Quan Hong; Fengmin Shao; Xiyao Shang; Bo Fu; Zhe Feng; Hongli Lin; Jianzhong Wang; Suozhu Shi; Zhong Yin; Xiangmei Chen
Journal:  Nephrol Dial Transplant       Date:  2008-03-08       Impact factor: 5.992

View more
  8 in total

1.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

2.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

3.  Stimulation of fibroblast proliferation by insoluble gadolinium salts.

Authors:  Katherine Bleavins; Patricia Perone; Madhav Naik; Muneeb Rehman; Muhammad N Aslam; Michael K Dame; Sasha Meshinchi; Narasimharao Bhagavathula; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-09-01       Impact factor: 3.738

4.  Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury.

Authors:  William Jenkins; Patricia Perone; Kyle Walker; Narasimharao Bhagavathula; Muhammad Nadeem Aslam; Marissa DaSilva; Michael K Dame; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-04-12       Impact factor: 3.738

5.  Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide.

Authors:  N Fretellier; Jm Idée; P Bruneval; S Guerret; F Daubiné; G Jestin; C Factor; N Poveda; A Dencausse; F Massicot; O Laprévote; C Mandet; N Bouzian; M Port; C Corot
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

6.  Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer.

Authors:  Bruce L Riser; Jeffrey L Barnes; James Varani
Journal:  J Cell Commun Signal       Date:  2015-12-23       Impact factor: 5.782

7.  Fibroblast response to gadolinium: role for platelet-derived growth factor receptor.

Authors:  Narasimharao Bhagavathula; Michael K Dame; Marissa DaSilva; William Jenkins; Muhammad N Aslam; Patricia Perone; James Varani
Journal:  Invest Radiol       Date:  2010-12       Impact factor: 6.016

Review 8.  Human Organ Culture: Updating the Approach to Bridge the Gap from In Vitro to In Vivo in Inflammation, Cancer, and Stem Cell Biology.

Authors:  Rafia S Al-Lamki; John R Bradley; Jordan S Pober
Journal:  Front Med (Lausanne)       Date:  2017-09-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.